It’s been quite a while since I talked about ex-vivo lung perfusion, but this was an interesting advance I saw posted a few days ago from the Pulmonary Fibrosis News website.

This actually improves on existing ex-vivo lung perfusion (EVLP) technology by using gene & cell therapy to rehabilitate & repair lungs that would otherwise be unsuitable for transplant.

This Business Wire press release gives more information on the companies involved & this exciting news.

Hopefully the successes of these companies in Toronto will soon be crossing the border to us soon.

Continue reading →